PEOPLE - Quidel makes appointment:
This article was originally published in Clinica
Executive Summary
Quidel (San Diego, California) has appointed Kenneth Buechler as a director of the board. Dr Buechler, who has a doctorate in biochemistry, joins the firm after 20 years at fellow US diagnostics company Biosite, where he was president and chief scientific officer prior to the firm's acquisition by Inverness earlier this year. Quidel discovers, develops, manufactures and markets rapid, point-of-care diagnostic tests in the areas of infectious diseases and reproductive health.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.